Successful antifungal combination therapy with voriconazole and caspofungin

Pediatr Blood Cancer. 2005 Jun 15;44(7):682-5. doi: 10.1002/pbc.20302.

Abstract

A 12-year-old boy in third remission of an acute lymphoblastic leukaemia developed infection of lung and paranasal sinuses with Aspergillus flavus in neutropenia. Because of the high risk of leukaemia-relapse bone marrow transplantation (BMT) from a matched unrelated donor was carried out despite invasive pulmonary aspergillosis (IPA). It is the first reported patient with IPA, who was successfully treated by the antifungal combination therapy with voriconazole and caspofungin therapy during myeloablative BMT. Despite 6 weeks of aplasia, a dramatic decrease of lesions highly suggestive of aspergillosis was observed after BMT. Since discharge-oral voriconazole monotherapy has been continued.

Publication types

  • Case Reports

MeSH terms

  • Antifungal Agents / therapeutic use*
  • Aspergillosis* / complications
  • Aspergillosis* / drug therapy*
  • Aspergillus / drug effects*
  • Caspofungin
  • Child, Preschool
  • Drug Therapy, Combination
  • Echinocandins
  • Humans
  • Lipopeptides
  • Lung Diseases, Fungal / drug therapy*
  • Lung Diseases, Fungal / etiology
  • Male
  • Peptides, Cyclic / therapeutic use
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Pyrimidines / therapeutic use
  • Triazoles / therapeutic use
  • Voriconazole

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Peptides, Cyclic
  • Pyrimidines
  • Triazoles
  • Caspofungin
  • Voriconazole